Neoadjuvant chemotherapy for ovarian cancer

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Chemotherapy

Background:

• Primary debulking surgery (PDS) is the standard of care for advanced ovarian cancer (AOC).
• Optimal debulking surgery is defined as achieving no residual tumor load.
• The role of neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is under investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of NACT followed by IDS compared to PDS in patients with AOC.
• To determine if IDS improves survival in patients who did not achieve optimal PDS.
• To assess the utility of open laparoscopy in evaluating operability for PDS and IDS.

Main Methods:

• Review of retrospective analyses and randomized trials, including EORTC-GCG and GOG 152.
• Analysis of patient outcomes based on surgical approach and chemotherapy regimen.
• Evaluation of open laparoscopy as a tool for surgical staging and operability assessment.

Main Results:

• Retrospective data suggest NACT followed by IDS may not worsen prognosis compared to PDS followed by chemotherapy.
• The EORTC-GCG trial indicates IDS improves survival in select patients not achieving optimal PDS.
• GOG 152 data suggest IDS may not be indicated for patients who underwent maximal surgical effort during PDS.

Conclusions:

• The optimal surgical strategy for advanced ovarian cancer, particularly stage IIIC and IV, requires further investigation through randomized trials.
• Interval debulking surgery can be beneficial for specific patient subgroups, especially those with suboptimal primary debulking.
• Open laparoscopy is a valuable tool for assessing surgical candidacy and operability in advanced ovarian cancer management.